Crónicas de autores

Martín Jesús García González *

Autor invitado por SIIC

Revisión sobre la utilidad potencial del levosimendan como agente terapéutico en la insuficiencia cardíaca generada por el atontamiento miocárdico de origen isquémico

TRATAMIENTO FARMACOLOGICO DEL ATONTAMIENTO MIOCARDICO: PAPEL POTENCIAL DEL LEVOSIMENDAN

El atontamiento miocárdico que se desencadena en el contexto de la reperfusión coronaria en los síndromes isquémicos agudos puede dar lugar a una situación de insuficiencia cardíaca, e incluso shock cardiogénico, cuyo tratamiento constituye un desafío clínico. El levosimendán, agente sensibilizante al calcio posee propiedades farmacocinéticas, farmacodinámicas y un perfil de seguridad que podrían ser de gran utilidad el tratamiento de esta situación clínica.

*Martín Jesús García González
describe para SIIC los aspectos relevantes de su trabajo
PHARMACOLOGIC TREATMENT OF HEART FAILURE DUE TO VENTRICULAR DYSFUNCTION BY MYOCARDIAL STUNNING
American Journal of Cardiovascular Drugs,
6(2):69-75, 2006

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Hospital Universitario de Canarias, Tenerife, España
Imprimir nota
Referencias bibliográficas
1. Heyndrickx Gr, Millard RW, McRitchie RJ, et al. Regional myocardial functional and electrophysiological alterations after a brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56:978-995.
2. Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 1982; 66:1146-1149.
3. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999; 79:609-634.
4. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994; 105:897-904.
5. Adamopoulos S, Parissis JT, Kremastinos DTh. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Failure 2001; 3:517-526.
6. Meldrum DR, Meng X, Dinarello CA, et al. Human myocardial tissue TNF-alpha expression following acute global ischemia in vivo. J Mol Cell Cardiol 1998; 30:1683-1689.
7. Manito N, Kaplinsky EJ, Pujol R. Tratamiento inotrópico en la insuficiencia cardíaca: aspectos generales y resultados clínicos. Med Clin (Barc) 2004; 122:269-274.
8. Taniyama Y, Ito H, Iwakura K, et al. Effects of intracoronary injection of verapamil and nicorandil on microcirculation and left ventricular function inpatients with reperfused myocardial infarction. (abstr) Circulation 1995; 92:177.
9. Sheiban I, Tonni S, Chizzoni A, et al. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. Cardiovasc Drugs Ther 1997; 11:5-16.
10. Barsotti A, Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion Ital Heart J 2004; 5(Suppl 2):29S-36S.
11. Donato M, Gelpi RJ. Adenosine and cardioprotection during reperfusion – an overview. Mol Cell Biochem 2003; 251:153-159.
12. Siegfried MR, Erhardt J, Rider T, et al. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther 1992; 260:668-675.
13. Klein HH, Pich S, Bohle RM, et al. Myocardial protection by Na(+)- H(+) exchange inhibition in ischemic, reperfused porcine hearts. Circulation 1995; 92:912-917.
14. Przyklenk K. Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. Coron Artery Dis 2001; 12:363-369.
15. Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997; 33:518-526.
16. Mannhold R. K-ATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 2004; 24:213-266.
17. Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care 2004; 10:436-441.
18. Auchampach JA, Maruyama M, Cavero I, et al. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992; 86:311-319.
19. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003; 63(23):2651-2671.
20. Rosevear PR, Finley N. Molecular mechanism of levosimendan action: an update. J Mol Cell Cardiol 2003; 35:1011-1015.
21. Ajiro Y, Hagiwara N, Katsube Y, et al. Levosimendan increases L-type Ca2+ current via phosphodiesterase – 3 inhibition in human cardiac myocytes. Eur J Pharmacol 2002; 435 (1):27-33.
22. Yokoshiki H, Katsube Y, Sunagawa M, et al. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283:375-383.
23. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. Coronary vasorelaxant effect of levosimendan, a new inodilatador with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31:741-749.
24. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-1912.
25. Parissis JT, Adamopoulos S, Antoniades Ch, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93:1309-1312.
26. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task Force on Acute Heart Failure of the European Society of Cardiology: ESC Committee for Practice Guidelines (CPG). Eur Heart J 2005; 26(4):384-416.
27. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (The LIDO study): a randomised double-blind trial. Lancet 2002; 360:196-202.
28. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAND). Eur Heart J 2002; 23:1422-1432.
29. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102:2222-2227.
30. Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Failure 2004; 6:501-508.
31. Cleland JGF, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, an PROACTIVE. Eur J Heart Fail 2006; 8:105-110.
32. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43:2177-2182.
33. Lehmann A, Lang J, Boldt J, et al. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10:89-93.
34. García González MJ, Domínguez Rodríguez A, Ferrer Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45:704-708.
Otros artículos de Martín Jesús García González

García González MJ, Domínguez Rodríguez A, Ferrer Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with st elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45:704-708.
García González MJ, Domínguez Rodriguez A, Abreu González P. Diurnal variations in serum neopterin levels are associated with the pineal hormone melatonin circadian rhythm in healthy human subjects. J Pineal Res 2006; 40(3):288-9.
García González MJ, Domínguez Rodríguez A, Ferrer Hita JJ, Abreu González P, Bethencourt Muñoz M. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006; 8:723-728.
Domínguez Rodríguez A, García González M, Abreu González P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97(1):10-12.
Domínguez Rodríguez A, Abreu González P, García González NJ, Ferrer Hita JJ. Asociación entre concentraciones séricas de interleucina 10 y desarrollo de insuficiencia cardíaca en pacientes con infarto agudo de miocardio tratados con angioplastia primaria. Rev Esp Cardiol 2005; 58(6):626-630.
Domínguez Rodríguez A, Abreu González P, García González MJ, Ferrer J, Vargas M. Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction. Clinical Biochemistry 2005; 38:180-182.
Domínguez Rodríguez A, Abreu González P, García González MJ, Ferrer Hita J, Vargas M, Reiter RJ. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal síntesis of melatonin in patients with myocardial infarction. Atherosclerosis 2005; 180:101-105.
Domínguez Rodríguez A, Abreu González P, García González M. Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction. Int J Cardiol 2006; 111:318-320.
Domínguez Rodríguez A, Abreu González P, García González M, Ferrer J. Prognostic value of interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention. Int J Cardiol 2006; 111:158-160.
Domínguez Rodríguez A, Abreu González P, García González M, Reiter RJ. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97:1162-1164.

Para comunicarse con Martín Jesús García González mencionar a SIIC como referencia:
mjgg181262@hotmail.com

Autor invitado
9 de junio, 2006
Descripción aprobada
16 de marzo, 2007
Reedición siicsalud
7 de junio, 2021

Acerca del trabajo completo
TRATAMIENTO FARMACOLOGICO DEL ATONTAMIENTO MIOCARDICO: PAPEL POTENCIAL DEL LEVOSIMENDAN

Título original en castellano
Tratamiento FarmacolOgico de la Insuficiencia Cardiaca debida a DisfunciOn Ventricular por Aturdimiento MiocArdico. Papel potencial del Levosimendan

Autor


Acceso a la fuente original
American Journal of Cardiovascular Drugs
http://link.springer.com/journal/40256

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317